Helicobacter Pylori Non-invasive Testing Market Revenue to

2022-11-27 02:56:18 By : Ms. Ling Nan

August 24, 2022 06:00 ET | Source: The Insight Partners The Insight Partners

New York, Aug. 24, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Helicobacter Pylori (H. Pylori) Non-Invasive Testing Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Test Type, Test Method End User and Geography,” however, the lack of skilled professionals hinders the market growth. Further, new product launches by competitive players are expected to offer significant growth opportunities to the market in the coming years. TB Antibody uncut sheet

Helicobacter Pylori Non-invasive Testing Market Revenue to

Get Sample PDF Copy of Helicobacter Pylori (H. pylori) Non-invasive Testing Market Size - COVID-19 Impact and Global Analysis with Strategic Developments at: https://www.theinsightpartners.com/sample/TIPRE00005185/

Helicobacter Pylori (H. pylori) Non-invasive Testing Market Report Scope & Strategic Insights:

Helicobacter Pylori (H. pylori) Non-Invasive Testing Market: Competitive Landscape and Key Developments

DiaSorin S.p.A; Meridian Bioscience, Inc.; QuidelOrtho Corporation; Abbott Laboratories; Thermo Fischer Scientific; CerTest Biotec; Sekisui Diagnostics; Coris BioConcept; Shenzhen Zhonghe Headway Bio-Sci & Tech Co., Ltd.; Bio-Rad Laboratories, Inc. are a few of the key companies operating in the global Helicobacter Pylori (H. pylori) non-invasive testing market. Leading players focus on expanding and diversifying their market presence and clientele, thereby tapping prevailing business opportunities.

Inquiry Before Purchase: https://www.theinsightpartners.com/inquiry/TIPRE00005185/

In March 2020, Meridian Bioscience, Inc. announced receiving approval from the FDA for Meridian’s new Curian and Curian HpSA assay. This analyzer and first assay play an important part in their initiative to maintain leadership in the gastrointestinal disease testing market.

In December 2021, Thermo Fischer Scientific announced the acquisition of PPD, Inc., a leading global provider of clinical research services to the biopharma & biotech industry, for US$ 17.4 billion.

North America is the largest market for Helicobacter Pylori (H. pylori) non-invasive testing across the globe. The growing prevalence of stomach cancer, duodenal ulcers, and gastric ulcers and the development of healthcare facilities are major growth stimulators for the market in North America. According to the National Institute of Health (NIH) report, the prevalence of H. pylori within the US comprises 5% prevalence in children less than 10 years. Additionally, the US Department of Health and Human Services report states that ~30-40% of people in the US suffer from H. pylori infection. Moreover, H. pylori infection is more common in the Hispanic and Black populations in the US due to socioeconomic factors, including low income, less education, household crowding, and immigration into the US. According to the ClinMed International Library report, the first-line drug regimens for the treatment of H. pylori by the Food and Drug Administration (FDA) include proton pump inhibitors (PPI) and two antibiotics or bismuth subsalicylate, acid suppressors, and two antibiotics. With approved first-line drug regimens, there exists resistance to utility. For example, the US recorded 75% eradication rates using these regimens owing to H. pylori resistance to standard antibiotics. For example, "Clarithromycin" and "Metronidazole" has the highest rate of resistance, and factors associated with resistance involve ethnicity, age, region, and active versus inactive ulcer disease.

Have a question? Speak to Research Analyst: https://www.theinsightpartners.com/speak-to-analyst/TIPRE00005185

In the US, 30-40% of patients undergoing bariatric surgery are infected with H. pylori, according to the estimates provided by Quest Diagnostics Incorporated. To overcome the high prevalence of H. pylori in the US, various top competitive players launched their innovative products intended for diagnostic tests involving a urea breath test, serology test, and stool antigen testing. For example, Thermo Fischer Scientific's innovative product, namely, "Oxoid Helicobacter Pylori Test Kit," is a rapid latex agglutination screening test intended for the qualitative detection of "Helicobacter Pylori" antibodies in serum. Such aforementioned factors are driving the growth of the overall Helicobacter Pylori (H. pylori) non-invasive testing market.

Rising Demand for Point-of-Care H. pylori Testing Boosts Overall Market Growth:

According to the National Institute of Health (NIH) report, noninvasive H. pylori diagnostic tests are available for point-of-care (POC) intended for primary care by involving IgG serology, C-urea breath test (UBT), and monoclonal stool antigen test. Among these, only UBT provides accuracy in confirming current infection or eradication. The Gut and Liver report shows that UBT is a non-invasive and accurate method that provides safety to pediatric patients and pregnant women. Also, point-of-care testing (POCT) is now a proven approach offering faster turnaround (TAT) of laboratory test results of H. pylori. With top competitive players continue to introduce new POCT technologies resulting in rising popularity, rise in testing among citizens, and diversity of available clinical applications. Moreover, POCT has routine applications in all hospitals, which is becoming the standard for patient care in various healthcare settings. Such aforementioned factors are responsible for the overall growth of the global Helicobacter Pylori (H. pylori) non-invasive testing market during the forecast period. Thus, the rising number of patients suffering from H. pylori is driving the growth of the market.

Avail Lucrative DISCOUNTS on “Helicobacter Pylori (H. pylori) Non-invasive Testing Market” Research Study: https://www.theinsightpartners.com/discount/TIPRE00005185/

Helicobacter Pylori (H. pylori) Non-invasive Testing Market: Segmental Overview

Based on test type, the Helicobacter Pylori (H. pylori) non-invasive testing market is segmented into serology, stool antigen, and urea breath. The urea breath segment accounted for the largest market share in 2021 and is expected to register the highest CAGR from 2022 to 2028. Based on test method, the market is bifurcated into laboratory based and point-of-care. The laboratory based segment led the market in 2021 and is expected to retain its dominance during the forecast period. Based on end user, the H. pylori market is segmented into hospitals, clinics, and diagnostic laboratories. The hospitals segment led the market in 2021 and is expected to retain its dominance during the forecast period.

The onset of the COVID-19 pandemic has challenged healthcare systems globally. However, the Helicobacter Pylori (H. pylori) non-invasive testing market has witnessed substantial growth amid the pandemic. For example, breath tests are simple, non-invasive alternatives and are considered harmless for diagnosing H. pylori infection, small intestinal bacterial overgrowth (SIBO), lactose intolerance, and inflammatory bowel disease in North America. The COVID-19 pandemic substantially influenced the H. pylori non-invasive testing market. This is mainly due to the presence of H. pylori in COVID-19 patients causing abdominal pain and diarrhea. SARS-CoV-2 enters cells through binding angiotensin-converting enzymes (ACE-2) receptors, and H. pylori are responsible for increasing the expression of ACE-2 receptors in the gastrointestinal tract. Therefore, with substantial relation between H. pylori and COVID-19, there has been considerable demand for H. pylori non-invasive testing, positively impacting the market revenue growth during the forecast period.

Directly Purchase Premium Copy of Helicobacter Pylori (H. pylori) Non-invasive Testing Market Growth Report at: https://www.theinsightpartners.com/buy/TIPRE00005185/

Non-invasive Breathing Technological Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type (Positive-pressure, Negative-pressure); End-User (as Hospital, clinics , Others)

Serological Testing Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Test Type (Primary Serological Tests, Secondary Serological Tests, Tertiary Binding Tests); Application (Rotavirus Infections, Hepatitis, HIV, Endotoxin, Therapeutic Drug Monitoring, Other Infectious Diseases); End Users (Hospitals, Diagnostic Laboratories, Blood Banks, Academic and Research Institutes, Others) and Geography

COVID-19 Serology Testing Market Forecast to 2028 - COVID-19 Impact and Global Analysis by Type (Neutralization Tests, Chemiluminescent Immunoassay (CLIA), Enzyme-linked Immunosorbent Assays (ELISAs), Rapid Diagnostic Test (RDT)); Application (Hospitals, Public Health Labs, Private or Commercial Labs, Physician Labs)

Bioanalytical Testing Services Market Forecast to 2028 - Covid-19 Impact and Global Analysis - By Type ( Cell Based Assays, Virology Testing, Serology, Immunogenicity and Neutralizing Antibodies, Toxicology Services, Biomarker Testing, Method Development Optimization and Validation, Metabolic Profiling and Mass Balance Studies, Pharmacokinetic Testing, Others ); Application ( Oncology, Immunology, Neurology, Hematology, Others ); End User ( Biopharmaceutical Companies, Clinical Research Organizations/Contract Research Organizations, Contract Development and Manufacturing Organization (CDMO) ) and Geography

Human Leukocyte Antigen (HLA) Testing Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product and Services (Reagents & Consumables, Instruments, and Software & Services), Technology [Molecular Assay Technologies (PCR-Based Molecular Assays, Sequencing-Based Molecular Assays, and Others) and Non-Molecular Assay Technologies], and End User (Independent Reference Laboratories, Hospitals and Transplant Centers, and Others), and Geography

Viral Antigens Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Component (Influenza Viral Antigens, Coronavirus Antigens, Zika Virus Antigens, Ebola Virus Antigens, Dengue Virus Antigens, Herpes Simplex Virus (HSV) Antigens, Rotavirus Viral Antigens, Hepatitis A-E Virus Antigens, Measles Virus Antigens, Mumps/Parotitis Virus Antigens, and Others); Technique (ELISA, Immunoassay, Hemagglutination, Radioimmunoassay (RIA), Immunoperoxidase Staining, Immunofluorescence, and Others); and End User (Hospitals, Clinics, Laboratories, Diagnostic Centers, Blood Banks, and Research Institutes); and Geography

About Us: The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us: If you have any queries about this report or if you would like further information, please contact us:

Helicobacter Pylori Non-invasive Testing Market Revenue to

Hiv Gp36 Antigen Contact Person: Sameer Joshi E-mail: sales@theinsightpartners.com Phone: +1-646-491-9876 Press Release: https://www.theinsightpartners.com/reports/pr/helicobacter-pylori-h-pylori-non-invasive-testing-market